Published in Obstet Gynecol on February 01, 2012
Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol (2013) 1.29
Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol (2014) 0.98
The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol (2013) 0.84
Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br J Cancer (2013) 0.82
Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol (2013) 0.81
Endometrial cancer. Obstet Gynecol Clin North Am (2012) 0.79
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection. J Gynecol Oncol (2015) 0.78
The effect of visceral obesity on clinicopathological features in patients with endometrial cancer: a retrospective analysis of 200 Chinese patients. BMC Cancer (2016) 0.78
Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer. J Magn Reson Imaging (2015) 0.77
Correlation of Minimum Apparent Diffusion Coefficient and Maximum Standardized Uptake Value of the Primary Tumor with Clinicopathologic Characteristics in Endometrial Cancer. Mol Imaging Radionucl Ther (2017) 0.75
Sentinel Lymph Node Mapping in Endometrial Cancer: An Update. Oncologist (2016) 0.75
Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma. Geburtshilfe Frauenheilkd (2016) 0.75
Implications of para-aortic lymph node metastasis in patients with endometrial cancer without pelvic lymph node metastasis. J Gynecol Oncol (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (2008) 8.12
Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer (1987) 5.36
Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet (2010) 5.05
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol (2009) 4.11
Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol (2008) 3.94
Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer (2006) 2.68
ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol (2005) 2.52
Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol (2000) 1.93
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75
Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol (2010) 1.20
The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol (2007) 1.13
Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer (2007) 1.11
Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. Gynecol Oncol (2011) 1.11
The risk of lymph node metastasis based on myometrial invasion and tumor grade in endometrioid uterine cancers: a multicenter, retrospective Korean study. Ann Surg Oncol (2009) 1.02
Lymph nodes: is total number or station number a better predictor of lymph node metastasis in endometrial cancer? Gynecol Oncol (2010) 0.89
Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol (2008) 0.88
Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol (1987) 0.86
Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution review. Ann Surg Oncol (2009) 0.79
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2004) 8.29
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Ovarian cancer. Lancet (2009) 3.95
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 3.39
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol (2003) 2.11
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol (2006) 2.07
Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004) 2.06
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer (2011) 2.02
Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol (2003) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol (2002) 1.93
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 1.92
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol (2013) 1.89
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol (2007) 1.80
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol (2010) 1.77
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.76
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol (2007) 1.70
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res (2012) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol (2012) 1.61
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer (2010) 1.61
Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol (2008) 1.57
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res (2012) 1.54
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res (2007) 1.51
Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol (2008) 1.50
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther (2009) 1.47
Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol (2008) 1.47
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol (2012) 1.46
Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol (2010) 1.46
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer (2010) 1.46
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol (2010) 1.45
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol (2006) 1.45
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol (2010) 1.43
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.42
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol (2006) 1.42
Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer (2009) 1.39
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther (2006) 1.38
Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res (2003) 1.37
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37
Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed. Arch Dermatol (2009) 1.36
Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.36
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.36
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2002) 1.34
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res (2007) 1.34
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol (2003) 1.33
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer (2011) 1.33
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.31
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol (2005) 1.31
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther (2009) 1.30
Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer (2008) 1.30
SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol (2010) 1.27
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res (2011) 1.26
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol (2008) 1.25
Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther (2010) 1.21
Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol (2003) 1.21
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol (2008) 1.19
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol (2013) 1.18
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ (2008) 1.17
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol (2009) 1.17
Management strategies for recurrent platinum-resistant ovarian cancer. Drugs (2011) 1.17
Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med (2007) 1.17
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.14
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 1.14
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer (2009) 1.13
Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer (2007) 1.11
Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol (2002) 1.11
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res (2007) 1.11